Synendos Therapeutics

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Synendos aims to develop breakthrough safe and effective therapies for neuropsychiatric disorders through the modulation of a new drug target that enables restoration of natural functioning of the brain. Synendos' current focus is on anxiety and mood-related diseases with high unmet medical need as post-traumatic stress disorder. Synendos advances the preclinical and clinical development of selective endocannabinoid reuptake inhibitors (first-in-class), which are covered by strong IP. An IND enabled, FIH, phase I trial is anticipated by 2022 and will be followed by Phase II. Synendos is developing a parallel de-risking strategy aimed at obtaining fast and cost-effective clinical PoC (Phase Ib) in a relevant CNS disease (small size, defined regulatory route, high unmet need and easy-to-assess endpoint). The financial strategy envisages CHF 20m to reach first clinical PoC. We identified two lead investors (term sheet available) and seek additional investors to complete the syndicate
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2019
Main Therapeutic Focus:
Lead Product in Development:
First-in-class inhibitors (small molecules)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO, co-founder
Synendos Therapeutics